-
公开(公告)号：US11224645B2
公开(公告)日：2022-01-18
申请号：US15555369
申请日：2016-03-22
IPC分类号： A61K39/008 , A61K47/64 , A61K39/00 , A61K39/385
摘要： Certain embodiments are directed to an immunogenic composition comprising an immunogenic glycoconjugate comprising a glycan having the chemical formula of galactopyranose (Galp)-α(1,2)-R, Galp-α(1,3)-R, Galp-α(1,4)-R, or Galp-α(1,6)-R, wherein in R is any monosaccharide, oligosaccharide, or polysaccharide, coupled to a carrier peptide or protein. Certain aspects described herein are directed to compounds and therapies for treating Leishmania infections. In certain aspects, the glycoconjugates as described herein, are incorporated into pharmaceutical compositions or vaccines
-
公开(公告)号：US20180043002A1
公开(公告)日：2018-02-15
申请号：US15555369
申请日：2016-03-22
IPC分类号： A61K39/008 , A61K39/385
CPC分类号： A61K39/008 , A61K39/385 , A61K47/6415 , A61K47/643 , A61K47/646 , A61K2039/545 , A61K2039/6037 , A61K2039/6081 , Y02A50/41
摘要： Certain embodiments are directed to an immunogenic composition comprising an immunogenic glycoconjugate comprising a glycan having the chemical formula of galactopyranose (Galp)-α(1,2)-R, Galp-α(1,3)-R, Galp-α(1,4)-R, or Galp-α(1,6)-R, wherein in R is any monosaccharide, oligosaccharide, or polysaccharide, coupled to a carrier peptide or protein. Certain aspects described herein are directed to compounds and therapies for treating Leishmania infections. In certain aspects, the glycoconjugates as described herein, are incorporated into pharmaceutical compositions or vaccines
-
公开(公告)号：US20170333568A1
公开(公告)日：2017-11-23
申请号：US15522631
申请日：2015-10-31
IPC分类号： A61K47/64 , G01N33/569
CPC分类号： A61K47/643 , A61K47/646 , G01N33/56905 , G01N2400/02 , Y02A50/55 , Y02A50/58
摘要： Certain embodiments are directed to method for synthesizing and using glycoconjugates on the immunodominant epitope Galα(1,3)Galβ(3(1,4)GlcNAcα (Galα3LNα).
-
公开(公告)号：US10918732B2
公开(公告)日：2021-02-16
申请号：US16523688
申请日：2019-07-26
IPC分类号： A61K47/64 , G01N33/569
摘要： Certain embodiments are directed to method for synthesizing and using glycoconjugates based on the immunodominant epitope Galα(1,3)Galβ(1,4)GlcNAcα (Galα3LNα).
-
公开(公告)号：US10363319B2
公开(公告)日：2019-07-30
申请号：US15522631
申请日：2015-10-31
IPC分类号： A61K47/64 , G01N33/569
摘要： Certain embodiments are directed to method for synthesizing and using glycoconjugates on the immunodominant epitope Galα(1,3)Galβ(3(1,4)GlcNAcα (Galα3LNα).
-
公开(公告)号：US20190111132A1
公开(公告)日：2019-04-18
申请号：US16164101
申请日：2018-10-18
申请人： Chunqiang Li , Thomas Boland , Hector P. Del Castillo , Katja Michael , Binata Joddar , Alfredo Ornelas
发明人： Chunqiang Li , Thomas Boland , Hector P. Del Castillo , Katja Michael , Binata Joddar , Alfredo Ornelas
IPC分类号： A61K41/00 , A61K31/404 , C08J3/24
摘要： A novel 34 amino acid long collagen-like peptide rich in proline, hydroxyproline, and glycine, and with several photoreactive N-acyl-7-nitroindoline units incorporated into the peptide backbone was synthesized by on-resin fragment condensation. The circular dichroism measurement of this peptide supports a stable triple helix structure. This peptide has potential as a new biomimetic material with built-in latent photochemical functions that enable the decomposition into small peptide fragments by illumination with UV light of 350 nm. Using a photoreactive glycine derivative as a model compound for the collagen-like peptide, we demonstrate that its photolysis can also be triggered by a two-photon absorption process using a femtosecond laser at 710 nm. When a thin film of this compound is irradiated with femtosecond laser light at 710 nm the photochemistry occurs only at locations of irradiation. In addition, the collagen-like peptide is able to support mesenchymal stem cell growth, indicating its non-toxicity to these cells and its potential in tissue engineering applications.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.015 秒)
